Chiesi reports significant international growth in 2015

31 March 2016

Italian family-owned drugmaker Chiesi Farmaceutici closed 2015 on a high note by reporting annual turnover of 1,467 million euros ($1.79 billion), an increase of more than 9.4% over the previous year, and earnings before interest, taxes, depreciation and amortization (EBITDA) equal to 407 million euros (a year-on-year increase of over 9%).

The robust health of the company is mirrored in its investment in innovation and development, with R&D expenditure rising by over 28% in the 2014-2015 period, from 236 million euros to 300 million euros, or 20% of total sales. The group currently has 41 active research and development projects.

Chiesi remains committed to the Italian market, and 2015 saw significant investment in Italy with 35 million euros spent on expanding a state-of-the-art production plant in Parma to meet demand for one of the group’s most successful products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK